Navigation Links
Carnegie Mellon's Christopher Bettinger Develops Edible Electronics for Medical Device Industry
Date:4/11/2013

PITTSBURGH, April 10, 2013 /PRNewswire/ -- It sounds futuristic, but today Carnegie Mellon University researchers are developing edible electronic devices that can be implanted in the body to improve patient care.

(Logo: http://photos.prnewswire.com/prnh/20020422/CMULOGO )

"We are creating electronically active medical devices that can be implanted in the body," said Christopher Bettinger , an assistant professor in the departments of Materials Science and Engineering and Biomedical Engineering at CMU. "The idea is for a patient to consume a pill that encapsulates the device."

Bettinger, along with Jay Whitacre , a professor of materials science and engineering, is creating edible power sources for medical devices that can be taken orally using materials found in the daily diet. 

"Our design involves flexible polymer electrodes and a sodium ion electrochemical cell, which allows us to fold the mechanism into an edible pill that encapsulates the device," Bettinger said.

CMU researchers report that the edible device could be programmed and deployed in the gastrointestinal tract or the small intestine depending upon packaging. Once the battery packaging is in place, Bettinger's team would activate the battery.

Bettinger reports that the battery could power biosensors to measure biomarkers or monitor gastric problems. The battery also could be used to stimulate damaged tissue or help in targeted drug delivery for certain types of cancer.

"There's so much out there we can do with this novel approach to medical devices," said Bettinger, a recipient of the National Academy of Sciences Award for Initiatives in Research for his innovative work on advanced materials for next-generation implanted medical devices.   

Bettinger has worked for more than a decade at the interface of materials science and biomedical engineering. Some of his innovative technologies include new synthetic materials that mimic the natural properties of soft tissue and biodegradable electronics that could usher in a new era of electronically active implants.  

For additional information about Bettinger, see www.materials.cmu.edu/people/bettinger.html

About Carnegie Mellon University: Carnegie Mellon (www.cmu.edu) is a private, internationally ranked research university with programs in areas ranging from science, technology and business, to public policy, the humanities and the arts. More than 12,000 students in the university's seven schools and colleges benefit from a small student-to-faculty ratio and an education characterized by its focus on creating and implementing solutions for real problems, interdisciplinary collaboration and innovation. A global university, Carnegie Mellon's main campus in the United States is in Pittsburgh, Pa. It has campuses in California's Silicon Valley and Qatar, and programs in Africa, Asia, Australia, Europe and Mexico. The university is in the midst of "Inspire Innovation: The Campaign for Carnegie Mellon University," which aims to build its endowment, support faculty, students and innovative research, and enhance the physical campus with equipment and facility improvements.

 


'/>"/>
SOURCE Carnegie Mellon University
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cohera Medical Named Winner of 2013 Carnegie Science Award
2. Carnegie Mellon University Biomedical Engineers Lead Collaborative Team Developing New Astro Surgery Tools for NASA Deep Space Missions
3. Parents Less Likely To Develop Colds, Carnegie Mellon Research Shows
4. Rethinking Research Ethics: Carnegie Mellon and McGill Researchers Challenge Post-marketing Trial Practices
5. Christopher Mennone Joins Surefire Medical Team As International Business Director
6. Zimmer Holdings Names Christopher Begley to Board of Directors
7. DART Therapeutics Develops Drug Candidate for Duchenne Muscular Dystrophy
8. Rady Venture Fund Develops Next Generation Tech Investors
9. UK Laboratory Develops Amazing Fetal Ultrasound Image Technology
10. AnaptysBio Develops Novel Antibody Scaffold With Extreme Thermostability
11. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Feb. 21, 2017  International Isotopes Inc. (OTCQB: INIS) ... placement with certain investors for approximately $3.4 million of ... Series C Convertible Redeemable Preferred Stock (the "Series C ... annual rate of 6% and is convertible into common ... use the proceeds for operating capital, to pay off ...
(Date:2/21/2017)... , Feb. 21, 2017 Research and Markets ... Devices - Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive ... , Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. Also, a ...
(Date:2/21/2017)... 21, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Uterine cancer Drugs Price Analysis and Strategies ... cancer market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Uterine cancer ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... ... Philpart, senior director at PolicyLink, will be the keynote speaker at its second ... and Men of Color Framework, which develops comprehensive strategies to create and expand ...
(Date:2/21/2017)... ... February 21, 2017 , ... Support of value-based care ... the secure exchange of data across industry solutions, Fogo Data Centers announces the launch ... community. A healthy community is one in which all systems work well, work ...
(Date:2/21/2017)... ... February 21, 2017 , ... HIMSS is ... connected care demonstration spanned multiple health information systems including OpenEMR, EMRDirect, and ... providers have no Health Information Exchange outside of faxing. Medal’s innovative technology “meets ...
(Date:2/20/2017)... ... February 20, 2017 , ... A new digital ... are called back for additional examinations without sacrificing cancer detection, according to a ... the U.S. Food and Drug Administration approved digital breast tomosynthesis (DBT) for use ...
(Date:2/20/2017)... ... February 20, 2017 , ... Scrubbing in for his first ... Dr. Christopher Pezzi remembers the excitement of the surgeon training him. , “He was ... to do this? Don’t tell anyone, but I would do it for free,’” Dr. ...
Breaking Medicine News(10 mins):